Is the onset of depression shortly after insertion of a hormonal intrauterine device (levonorgestrel‑releasing IUD) potentially related to the device?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Depression Onset Related to Levonorgestrel IUD

Yes, the onset of depression shortly after insertion of a levonorgestrel-releasing IUD (LNG-IUD) is potentially related to the device, particularly in adolescents and first-time hormonal contraceptive users, though the absolute risk remains uncertain and individual susceptibility varies considerably.

Evidence from Guidelines

The U.S. Medical Eligibility Criteria for Contraceptive Use (2010) classifies depressive disorders as Category 1 for both LNG-IUD initiation and continuation, meaning the advantages generally outweigh theoretical or proven risks 1. However, this classification acknowledges that "no data were available on bipolar disorder or postpartum depression" and notes that "drug interactions potentially can occur between certain antidepressant medications and hormonal contraceptives" 1.

This guideline classification predates the most recent and concerning research evidence, which emerged after 2018.

Critical Recent Research Evidence

The strongest and most recent evidence comes from a 2023 Swedish nationwide cohort study of 703,157 women aged 15-24 years, which found:

  • 57% increased risk of depression with LNG-IUD use [AHR 1.57,95% CI 1.51-1.64] 2
  • 157% increased risk in adolescents [AHR 2.57,95% CI 2.36-2.80] 2
  • 63% increased risk when used as first-ever hormonal contraceptive [AHR 1.63,95% CI 1.50-1.78] 2

A 2024 Danish study demonstrated dose-dependent effects, with the high-dose 52mg LNG-IUS showing significantly higher depression rates (30.8 per 1,000 person-years) compared to low-dose formulations (19.8 and 17.7 per 1,000 person-years for 19.5mg and 13.5mg respectively) 3.

Additional research from 2018 found associations between levonorgestrel exposure and anxiety (HR 1.18,95% CI 1.08-1.29) and sleep problems (HR 1.22,95% CI 1.08-1.38) 4.

Clinical Algorithm for Assessment

When evaluating new-onset depression after LNG-IUD insertion:

  1. Establish temporal relationship: Depression onset within 3-6 months of insertion is most concerning

  2. Identify high-risk patients:

    • Age <24 years (especially adolescents)
    • First-time hormonal contraceptive users
    • High-dose (52mg) LNG-IUD users
    • No prior psychiatric history (paradoxically at higher risk)

  3. Rule out other causes:

    • New medications or medical conditions
    • Psychosocial stressors
    • Thyroid dysfunction
    • Anemia from bleeding changes

  4. Consider device removal if:

    • Moderate to severe depressive symptoms emerge
    • Symptoms persist beyond 3 months
    • Patient desires removal after counseling
    • Symptoms interfere with functioning or quality of life

Important Caveats

The evidence has significant limitations:

  • Most studies are observational and cannot prove causation
  • Confounding by indication is likely (women seeking contraception may differ from non-users)
  • The Swedish study showed decreasing risk over time as LNG-IUD became more accessible, suggesting selection bias 2
  • Individual susceptibility varies enormously

However, the consistency across multiple large studies, the dose-response relationship, and the temporal association support biological plausibility.

Practical Recommendations

Before LNG-IUD insertion:

  • Screen for personal and family psychiatric history
  • Counsel specifically about depression risk, especially in adolescents
  • Consider low-dose formulations (13.5mg or 19.5mg) over 52mg for contraceptive purposes 3
  • Document baseline mood status

After insertion:

  • Monitor mood symptoms at 3-6 month follow-up
  • Advise patients to report new anxiety, sleep disturbances, or depressive symptoms
  • Maintain low threshold for device removal if psychiatric symptoms emerge
  • Do not dismiss patient concerns about mood changes

The copper IUD remains an excellent non-hormonal alternative for patients concerned about psychiatric effects or with psychiatric history 1, 5.

While guidelines classify LNG-IUD as safe for women with depressive disorders, the emerging evidence from 2023-2024 suggests greater caution is warranted, particularly in young, first-time users 2, 3. The priority must be patient quality of life and mental health, even when contraceptive efficacy is excellent.

References

1
Guideline

u s. medical eligibility criteria for contraceptive use, 2010.

MMWR Recommendations and Reports, 2010

2
Research

Levonorgestrel intrauterine device and depression: A Swedish register-based cohort study.

International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 2023

5
Guideline

contraception for adolescents.

Pediatrics, 2014

Related Questions

Does a hormonal intrauterine device (levonorgestrel-releasing intrauterine system) worsen anxiety?
Which hormone tests should be ordered to evaluate abnormal endocrine levels contributing to anxiety and depression in a woman using a levonorgestrel‑releasing intrauterine device?
Should a levonorgestrel‑releasing Kyleena intrauterine device be removed in a 12‑year‑old female with Down syndrome who developed new‑onset anger outbursts, auditory hallucinations, aggression, and school avoidance one month after insertion, and what further evaluation is recommended?
What estrogen and progesterone levels are considered abnormal in a patient with a Mirena (levonorgestrel) IUD who is experiencing mood, sleep, and anxiety issues?
Why does high-dose levonorgestrel increase the risk of depression?
At what gestational week can the fetal sex be determined?
What is the appropriate adult treatment regimen, including dose and duration, for streptococcal pharyngitis?
What is the optimal management for a patient with coexisting COPD and asthma who is currently using Symbicort (budesonide/formoterol) 80 µg/4.5 µg inhaler and continues to cough?
What is the appropriate brand name (with generic name) for single‑inhaler triple therapy and what is the comprehensive management plan?
Is Trilogy 200 (budesonide 200 µg / glycopyrrolate 50 µg / formoterol 12 µg) appropriate for a patient with moderate‑to‑severe chronic obstructive pulmonary disease, CAT score ≥10, mMRC grade ≥2, post‑bronchodilator FEV1 <80 % predicted, and a history of ≥2 moderate or ≥1 severe exacerbation in the past year, and what additional therapies or measures should be added to the management plan?
At what platelet count should tinzaparin (Fraxiparine) prophylaxis for deep vein thrombosis be stopped?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.